ArticleMedical oncology (Northwood, London, England)2026
Exosomes derived from itaconate-treated macrophages promote epithelial-mesenchymal transition, migration, and invasion in MCF-7 breast cancer cells.
Article in Medical oncology (Northwood, London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Itaconic acid is an immunometabolite that regulates macrophage polarization within the tumor microenvironment and influences tumor progression and invasion. Although its anti-cancer and tumor-promoting effects remain controversial, its role in modulating macrophage-derived exosomes and their impact on breast cancer cells is not well understood. This study investigated the effects of exosomes derived from dimethyl itaconate (DMI)-treated macrophages on epithelial-mesenchymal transition (EMT), apoptosis, migration, and EMT-related miRNAs in MCF7 breast cancer cells. U937 macrophages were treated with 250 µM DMI for 48 h. Exosomes (DMI-EXO) were subsequently isolated, characterized, and used to treat MCF7 cells. The expression of EMT-related proteins (E-cadherin, N-cadherin, ZEB1/2, Slug, and Vimentin) and EMT-associated miRNAs (miR200C-5p, miR30C-5p, miR-638, and miR-137) was evaluated by Western blotting and quantitative real-time PCR, respectively. Apoptosis, cell migration, and invasion were assessed using Annexin V/PI staining, the scratch wound-healing assay, and the Transwell invasion assay, respectively. DMI-EXO treatment significantly increased the expression of the mesenchymal markers N-cadherin, ZEB1/2, Slug, and Vimentin while reducing the epithelial marker E-cadherin. In addition, the expression of EMT-suppressive miRNAs, including miR200C-5p and miR30C-5p, was significantly decreased, whereas no significant change was observed in miR-137 expression following DMI-EXO treatment. DMI-EXO treatment did not significantly alter apoptosis in MCF-7 cells but enhanced cell migration and invasion, as demonstrated by accelerated wound closure in the scratch assay and increased invaded area in the Transwell invasion assay. These findings indicate that DMI-induced macrophage-derived exosomes promote EMT and migration in breast cancer cells by modulating EMT-related proteins and miRNAs. This study provides new evidence that itaconic acid may facilitate breast tumor progression through exosome-mediated communication between macrophages and cancer cells.
Indexed as
Identifiers
42900452What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.